This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
← catalyst calendarNCT06758401 · readout in 748 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
714estimated
Sites
372
Countries
Argentina, Australia, Austria +28
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-23 | actual | When the study began enrolling |
| Primary completion | 2028-09-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions
- Drug: Sigvotatug Vedotin
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFOverall Survival
measured Baseline to date of death from any cause (Approximately 2 years)
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
measured From Baseline to to date of first documentation of progression OR death (Approximately 2 year)
Publications
- PMID 41388832 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed